Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009; NCT02684032).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Alabama at Birmingham, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Massachusetts General Hospital, Compassionate Cancer Care, University of Colorado Denver, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Pfizer (United States), University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2624499646